Results 41 to 50 of about 20,836,880 (230)

Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting [PDF]

open access: yesBioMed Research International, 2014
The field of oral anticoagulation has evolved with the arrival of non-vitamin K antagonist oral anticoagulants (NOACs) including an anti-IIa agent (dabigatran etexilate) and anti-Xa agents (rivaroxaban and apixaban). The main specificities of these drugs are predictable pharmacokinetics and pharmacodynamics but special attention should be paid in the ...
Anne-Sophie Dincq   +5 more
openaire   +3 more sources

Baseline characteristics of patients treated with warfarin vs. non-vitamin K antagonist oral anticoagulants (NOACs).

open access: yes, 2019
Baseline characteristics of patients treated with warfarin vs. non-vitamin K antagonist oral anticoagulants (NOACs).
Robert Klempfner (326258)   +4 more
core   +1 more source

How to effectively reverse life-thretening effects of non-vitamin K oral anticoagulants?

open access: yesJournal of Education, Health and Sport, 2017
For several decades the vitamin K antagonist oral anticoagulants were the only outpatient therapy that existed to reduce the risk of stroke and thromboembolism until non-vitamin K oral anticoagulants (NOACs).
Łukasz Wołowiec   +5 more
doaj   +3 more sources

Non–Vitamin K Antagonist Oral Anticoagulants: The Clinician’s New Challenge

open access: yesJournal of Osteopathic Medicine, 2015
Abstract Millions of US patients are prescribed oral anticoagulants. Traditionally, oral anticoagulation was achieved with vitamin K antagonists (VKAs). In recent years, non–VKA oral anticoagulants (NOACs) have emerged that provide an effective and convenient alternative to VKAs.
Brian K, Yorkgitis   +2 more
openaire   +2 more sources

Similar outcomes between vitamin K and non-vitamin K antagonist oral anticoagulants associated intracerebral hemorrhage

open access: yesJournal of the Formosan Medical Association, 2020
Background: The application of non-vitamin K antagonist oral anticoagulant (NOAC) reduces the risk of intracerebral hemorrhage (ICH) in comparison with vitamin K antagonist (VKA).
Szu-Ju Chen   +5 more
doaj   +1 more source

Pooled characteristics of patients suffering acute cerebral ischemic events while taking non-vitamin K antagonist oral anticoagulants (N = 12247).

open access: yes, 2019
Pooled characteristics of patients suffering acute cerebral ischemic events while taking non-vitamin K antagonist oral anticoagulants (N = 12247).
Simon Jung (672063)   +7 more
core   +1 more source

Prevention of thromboembolic complications in patients with atrial fibrillation and obesity

open access: yesAnnales Academiae Medicae Silesiensis, 2023
Atrial fibrillation (AF) is an arrhythmia that occurs in 1–2% of the population. Chronic oral anticoagulation is recommended in the group of patients with AF to prevent thromboembolic complications. Obesity is a factor contributing to the development and
Izabela Kolasa, Beata Średniawa
doaj   +1 more source

Non-vitamin K antagonist oral anticoagulants in adults with a Fontan circulation: are they safe [PDF]

open access: yesOpen Heart, 2019
Background In Fontan patients with atrial arrhythmias (AA), non-vitamin K antagonist oral anticoagulants(NOACs) have a class III recommendation according to the Pediatric & Congenital Electrophysiology Society (PACES)/Heart Rhythm Society (HRS) guideline in 2014, due to lack of data on outcomes as opposed to ...
Yang, Hayang   +18 more
openaire   +10 more sources

Non-Vitamin K Oral Anticoagulants (NOACs)

open access: yes, 2023
Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) have revolutionized the field of anticoagulation therapy, offering a significant advancement over conventional anticoagulants like warfarin.
Elias, Ala
core  

Characteristics in Non–Vitamin K Antagonist Oral Anticoagulant–Related Intracerebral Hemorrhage [PDF]

open access: yesStroke, 2019
Background and Purpose— Given inconclusive studies, it is debated whether clinical and imaging characteristics, as well as functional outcome, differ among patients with intracerebral hemorrhage (ICH) related to vitamin K antagonists (VKA) versus non–vitamin K antagonist (NOAC)-related ICH.
Gerner, Stefan T.   +60 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy